CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
B 细胞血液系统恶性肿瘤患者 CAR-T 细胞治疗后细胞因子释放综合征的预后意义
英文原题：Prognostic Significance of Cytokine Release Syndrome in B Cell Hematological Malignancies Patients After Chimeric Antigen Receptor T Cell Therapy.
查看英文原题
Prognostic Significance of Cytokine Release Syndrome in B Cell Hematological Malignancies Patients After Chimeric Antigen Receptor T Cell Therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
细胞因子释放综合征（CRS）是嵌合抗原受体（CAR）T细胞治疗最常见的靶向毒性。然而，CRS的预后意义尚未得到充分阐明。我们研究的目的是在一个包含22例复发/难治性B细胞血液系统恶性肿瘤患者的回顾性队列中，评估抗CD19 CAR-T 治疗后CRS与疗效之间的关联。CAR-T 治疗后的完全缓解（CR）率为68%，无进展生存期（PFS）的中位值为6.8个月。22例患者中有8例（36.4%）表现为2级CRS。统计分析发现，2级CRS患者的CR率高于<2级CRS患者，PFS也更长。此外，桥接造血干细胞移植是PFS的另一项独立预测因素。这些数据提示，适当的CRS可能有利于CAR-T 治疗的疗效。临床试验注册号为NCT03110640、NCT03302403。
展开英文摘要原文
Cytokine release syndrome (CRS) is the most common on-target toxicity of chimeric antigen receptor (CAR) T cell therapy.
However, the prognostic significance of CRS has not been well elucidated. The aim of our study was to evaluate the association between CRS and efficacy after anti-CD19 CAR-T therapy in a retrospective cohort of 22 patients with relapsed/refractory B cell hematological malignancies.
The complete remission (CR) rates after CAR-T therapy were 68%, and median value for progression-free survival (PFS) was 6. 8 months. Eight of 22 (36. 4%) patients showed grade 2 CRS. Statistical analysis found that patients with grade 2 CRS had higher CR rates and longer PFS than those with < grade 2 CRS.
Moreover, bridging hematopoietic stem cell transplantation was another independent predictor for PFS. These data suggested that appropriate CRS may be beneficial to the efficacy of CAR-T therapy. The Clinical Trial Registration number is NCT03110640, NCT03302403.
论文信息
- 作者
- Dong R、Jiang S、Chen Y、Ma Y、Sun L、Xing C、Zhang S、Yu K
- 单位
- Department of Hematology, Wenzhou Key Laboratory of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.China
- 文献类型
- 非美国政府资助研究
- 期刊
- Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research2021 Dec
- 原文标识
- PubMed 34935483 · DOI 10.1089/jir.2021.0057